Table 2 |
||||||
|
IFN-γ levels in the tuberculosis antigen-stimulated wells and mitogen-stimulated wells that were used as positive controls |
||||||
|
RA-TNF1 (n = 38) |
RA-TNF2 (n = 38) |
TNF-naive RA (n = 40) |
TB (n = 30) |
Leprosy (n = 23) |
Healthy controls (n = 41) |
|
|
|
||||||
|
IFN-γ level in tuberulosis antigen well (IU/ml) |
3.6 ± 8.4 |
3.0 ± 6.2 |
2.8 ± 5 |
2.3 ± 4.2 |
7.3 ± 8.0 |
3.5 ± 6.4 |
|
IFN-γ level in positive control well (IU/ml) |
7.0 ± 6.4 |
16.1 ± 14.2a |
8.7 ± 6.1 |
11.6 ± 12.1 |
12.2 ± 6.1 |
17.3 ± 6.4 |
|
|
||||||
|
aThe mitogen-nil level increased significantly (P < 0.001) after treatment with TNF-α antagonists. |
||||||
|
Hatemi et al. Arthritis Research & Therapy 2012 14:R147 doi:10.1186/ar3882 |
||||||
